Literature DB >> 16297204

Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation.

Daniel B Yarosh1, Arely V Pena, Stephanie L Nay, Matthew T Canning, David A Brown.   

Abstract

The use of calcineurin inhibitors in solid organ transplantation results in an increased risk of skin cancer. We examined the effect of these drugs on DNA repair in normal human keratinocytes after ultraviolet B (UVB) irradiation. We found that both cyclosporine A (CsA) and ascomycin inhibited removal of cyclobutane pyrimidine dimers, and that they also inhibited UVB-induced apoptosis. We also observed that UVB induced nuclear localization of the transcription factor nuclear factor of activated T-cells (NFAT), and that this was blocked by CsA and ascomycin. These data suggest that the increased risk of skin cancer observed in organ-transplant patients may be as a result of not only systemic immune suppression but also the local inhibition of DNA repair and apoptosis in skin by calcineurin inhibitors. These findings may have implications for the use of topical calcineurin inhibitors in sun-exposed skin and eyes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297204     DOI: 10.1111/j.0022-202X.2005.23858.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  40 in total

Review 1.  Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.

Authors:  Christophe Carenco; Stéphanie Faure; José Ursic-Bedoya; Astrid Herrero; Georges Philippe Pageaux
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair.

Authors:  Matthew T Canning; Stephanie L Nay; Arely V Peña; Daniel B Yarosh
Journal:  J Mol Histol       Date:  2006-08-23       Impact factor: 2.611

3.  NFATc1 balances quiescence and proliferation of skin stem cells.

Authors:  Valerie Horsley; Antonios O Aliprantis; Lisa Polak; Laurie H Glimcher; Elaine Fuchs
Journal:  Cell       Date:  2008-01-25       Impact factor: 41.582

4.  Chromosomal aberrations in UVB-induced tumors of immunosuppressed mice.

Authors:  Amy M Dworkin; Kathleen L Tober; F Jason Duncan; Lianbo Yu; Anne M VanBuskirk; Tatiana M Oberyszyn; Amanda Ewart Toland
Journal:  Genes Chromosomes Cancer       Date:  2009-06       Impact factor: 5.006

5.  Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.

Authors:  Brian C Wulff; Jennifer M Thomas-Ahner; Jonathan S Schick; Tatiana M Oberyszyn
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

6.  Deregulation of XPC and CypA by cyclosporin A: an immunosuppression-independent mechanism of skin carcinogenesis.

Authors:  Weinong Han; Keyoumars Soltani; Mei Ming; Yu-Ying He
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-30

7.  Cyclosporin-A associated malignancy.

Authors:  Jonathan M Durnian; Rosalind M K Stewart; Richard Tatham; Mark Batterbury; Stephen B Kaye
Journal:  Clin Ophthalmol       Date:  2007-12

8.  A modified fluorimetric host cell reactivation assay to determine the repair capacity of primary keratinocytes, melanocytes and fibroblasts.

Authors:  Katharina Burger; Katja Matt; Nicole Kieser; Daniel Gebhard; Jörg Bergemann
Journal:  BMC Biotechnol       Date:  2010-06-22       Impact factor: 2.563

9.  Forskolin protects keratinocytes from UVB-induced apoptosis and increases DNA repair independent of its effects on melanogenesis.

Authors:  Thierry Passeron; Takeshi Namiki; Hélène J Passeron; Elodie Le Pape; Vincent J Hearing
Journal:  J Invest Dermatol       Date:  2008-06-26       Impact factor: 8.551

10.  NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure.

Authors:  R J Flockhart; B L Diffey; P M Farr; J Lloyd; N J Reynolds
Journal:  FASEB J       Date:  2008-08-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.